Altis Labs AI Imaging Endpoint Predicts Overall Survival Benefit in Phase 3 Lung Cancer Trial: Data Presented at IASLC WCLC 2026

TORONTO — Altis Labs, Inc. (“Altis”), the AI endpoint company accelerating clinical trials, today announced findings from an independent post-hoc analysis evaluating its AI-powered imaging endpoint, IPRO, in the MARIPOSA Phase 3 trial. 1 The findings, which were presented at the World Conference on Lung Cancer (WCLC) 2026 in Seoul, Republic of Korea, show that Altis’ IPRO Response Rate detected an early, notable treatment effect, while RECIST-based objective response rate (ORR) failed to anticipate the investigational treatment’s 12+ month median overall survival (OS) benefit.

A welcome email is on its way. If you don't see it, please check your junk folder.

In a post-hoc analysis performed by the trial sponsor, IPRO demonstrated its value as an early endpoint in the trial, which compared treatments in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC). The IPRO AI model automatically analyzed approximately 10,000 radiology scans, generating prognostic outcome measures for each patient at baseline and on-treatment assessments. IPRO Response was defined as a ≥50% improvement in the IPRO-α score relative to baseline, and the treatment effect was estimated as the IPRO Response Rate ratio for the investigational treatment versus control arm treatment at landmark early imaging assessments.

“This readout proves that AI can anticipate meaningful clinical benefit that traditional imaging endpoints like ORR may fail to detect,” said Felix Baldauf-Lenschen, Founder and CEO of Altis Labs. “We’re focused on supporting our biopharma partners and ultimately patients by bringing this level of precision into clinical trials so that efficacy can be detected earlier.”

The results were presented on September 13th, 2026, at WCLC, Abstract/Poster: P1.046: IPRO-a Response Rate as a Potential Early Endpoint for Overall Survival in MARIPOSA, a Phase 3 Trial in EGFR-Mutated NSCLC. Abstract can be viewed at: https://cattendee.abstractsonline.com/meeting/21487/Presentation/3918 About IPRO IPRO is a fully automated AI system that predicts patient survival directly from the CT scans already acquired in clinical trials. Rather than automating RECIST, IPRO goes beyond measuring target lesion size by analyzing the entire three-dimensional scan to quantify thousands of prognostic imaging biomarkers spanning tumor burden, body composition, and organ health that contribute to multifactorial survival outcomes. At the patient-level, improvements in IPRO (i.e. IPRO Response) are associated with survival benefit, while IPRO deterioration is associated with survival detriment. Clinical trial sponsors use IPRO Response Rate as a novel, survival-linked endpoint to detect early efficacy signals and navigate go/no-go decisions with greater confidence.

NSCLC accounts for up to 85% of all lung cancer cases worldwide and is the leading cause of cancer death. Epidermal growth factor receptor (EGFR) alterations represent one of the most common driver mutations, found in 10% to 15% of Western patients and up to 40% to 50% of Asian patients with adenocarcinoma histology.